Overview
Alloimmune platelet transfusion refractoriness occurs when recipients develop antibodies against donor platelets, leading to ineffective platelet transfusions despite adequate platelet counts. This condition complicates management and increases transfusion requirements 1.Diagnosis
Key Diagnostic Criteria: Presence of alloantibodies against donor platelets, confirmed by serological testing such as platelet immunofluorescence microscopy or flow cytometry 1.
Recommended Tests:
- Serological testing for platelet-specific alloantibodies.
- Crossmatch testing to identify compatible platelet units.
- Evaluation of platelet survival using radiolabeled platelets or flow cytometry 1.
Grading: Severity often graded based on clinical bleeding manifestations and laboratory findings, though standardized grading systems are not detailed in the provided abstracts 1.Management
First-Line Treatments:
- Identification and transfusion of compatible platelet units through meticulous crossmatching.
- Use of HLA-matched platelets when available 1.
Adjunctive Treatments:
- Immune tolerance induction with intravenous immunoglobulin (IVIG) or anti-CD20 monoclonal antibodies (e.g., rituximab) in refractory cases 1.
- Consideration of alternative therapies like cytokine modulation or splenectomy in severe, refractory cases, though specific dosing details are not provided 1.Special Populations
Pediatrics: Elevated microparticle content (MPC) in donor platelets can reduce transfusion efficacy, particularly in children with systemic inflammation; monitoring MPC using technologies like ThromboLUX may guide better management 2.
Comorbidities: No specific recommendations for elderly or comorbid conditions are detailed in the provided abstracts 12.Key Recommendations
Implement Diagnostic Management Teams (DMTs) for streamlined workup and management of platelet refractory patients to improve diagnostic accuracy and timely treatment (Evidence: Expert opinion) 1.
Consider microparticle content in donor platelets, especially in pediatric transfusions, to enhance transfusion efficacy (Evidence: Moderate) 2.
Utilize meticulous crossmatching and HLA-matched platelets to identify and transfuse compatible units in alloimmune refractory cases (Evidence: Expert opinion) 1.References
1 Wade J, Dean CL, Krummey SM, Roback JD, Sullivan HC. How do I … implement diagnostic management teams in transfusion medicine?. Transfusion 2020. link
2 Kanzler P, Mahoney A, Leitner G, Witt V, Maurer-Spurej E. Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children - A study proposal. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2017. link